FROFrontline plc

NYSE frontline.bm


$ 23.31 $ 0.07 (0.3 %)    

Tuesday, 17-Sep-2024 15:39:10 EDT
QQQ $ 472.78 $ -3.19 (-0.67 %)
DIA $ 416.60 $ -1.39 (-0.33 %)
SPY $ 562.14 $ -2.99 (-0.53 %)
TLT $ 100.93 $ -0.46 (-0.45 %)
GLD $ 237.38 $ -0.60 (-0.25 %)
$ 23.22
$ 23.24
$ 23.31 x 100
$ 23.32 x 103
$ 23.14 - $ 23.40
$ 15.09 - $ 27.90
1,849,821
na
5.17B
$ 0.92
$ 7.88
TBD
na
na ($ 0.08)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jefferies-maintains-buy-on-frontline-maintains-30-price-target

Jefferies analyst Omar Nokta maintains Frontline (NYSE:FRO) with a Buy and maintains $30 price target.

 frontline-navigates-choppy-waters-q2-revenue-soars-but-eps-sinks-in-spicy-tanker-market

Frontline reported Q2 FY24 revenue of $607.5 million, beating consensus. Net operating income improved, but adjusted EPS missed...

 frontline-q2-2024-adj-eps-062-misses-067-estimate-sales-607513m-beat-382322m-estimate

Frontline (NYSE:FRO) reported quarterly earnings of $0.62 per share which missed the analyst consensus estimate of $0.67 by 7.4...

 evercore-isi-group-maintains-outperform-on-frontline-lowers-price-target-to-32

Evercore ISI Group analyst Jonathan Chappell maintains Frontline (NYSE:FRO) with a Outperform and lowers the price target fr...

 jefferies-maintains-buy-on-frontline-maintains-30-price-target

Jefferies analyst Omar Nokta maintains Frontline (NYSE:FRO) with a Buy and maintains $30 price target.

 enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

 micron-to-rally-around-134-here-are-10-top-analyst-forecasts-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 jefferies-upgrades-frontline-to-buy-raises-price-target-to-30

Jefferies analyst Omar Nokta upgrades Frontline (NYSE:FRO) from Hold to Buy and raises the price target from $22 to $30.

 jp-morgan-maintains-neutral-on-frontline-lowers-price-target-to-223

JP Morgan analyst Samuel Bland maintains Frontline (NYSE:FRO) with a Neutral and lowers the price target from $23 to $22.3.

 frontline-outperforms-q4-revenue-estimates-strategic-asset-sales-and-refinancing-bolster-financial-position

Frontline Plc reported Q4 revenue of $415M, beating consensus of $270.06M. Net income, EPS, and cash flow all decreased compare...

 jefferies-reiterates-hold-on-frontline-maintains-22-price-target

Jefferies analyst Omar Nokta reiterates Frontline (NYSE:FRO) with a Hold and maintains $22 price target.

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 jp-morgan-maintains-neutral-on-frontline-lowers-price-target-to-23

JP Morgan analyst Samuel Bland maintains Frontline (NYSE:FRO) with a Neutral and lowers the price target from $24 to $23.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION